RJFSA
TMBR

Raymond James Financial Services Advisors’s Timber Pharmaceuticals, Inc. TMBR Stock Holding History

Raymond James Financial Services Advisors’s Portfolio TMBR Stock Details TMBR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-300
Closed -$18K – 3445
2021
Q2 		$18K Hold
300
– – ﹤0.01% 3263
2021
Q1 		$30K Buy
+300
New +$25.8K ﹤0.01% 3127

Other funds holding TMBR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Raymond James Financial Services Advisors's TMBR Position: Q3 2021 in Review

Raymond James Financial Services Advisors sold out of Timber Pharmaceuticals, Inc. (TMBR) in Q3 2021, closing a stake of 300 shares — an estimated $18K sold.

Raymond James Financial Services Advisors first reported a position in TMBR in Q1 2021 and held it in 2 quarters. The position peaked at $30K in Q1 2021. 17 funds tracked by Wall St. Rank hold TMBR as of Q3 2021.

  • Raymond James Financial Services Advisors reported no remaining Timber Pharmaceuticals, Inc. position as of Q3 2021 after selling out during the quarter.
  • Raymond James Financial Services Advisors sold 300 Timber Pharmaceuticals, Inc. shares in Q3 2021, an estimated $18K.
  • Raymond James Financial Services Advisors first reported a position in Timber Pharmaceuticals, Inc. in Q1 2021 and held it in 2 quarters.
  • Raymond James Financial Services Advisors's Timber Pharmaceuticals, Inc. position peaked at $30K in Q1 2021.
  • 17 funds tracked by Wall St. Rank held Timber Pharmaceuticals, Inc. as of Q3 2021.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2021, filed 2 Nov 2021.